# Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

> **NCT00234143** · PHASE2,PHASE3 · UNKNOWN · sponsor: **St. Bartholomew's Hospital** · enrollment: 360 (estimated)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **BEHAVIORAL:** Darbepoetin and Filgrastim
- **DRUG:** Darbepoetin

## Key facts

- **NCT ID:** NCT00234143
- **Lead sponsor:** St. Bartholomew's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2009-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00234143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00234143, "Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00234143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*